FDA open to use of new MRD end­point ahead of ad­vi­so­ry com­mit­tee meet­ing

The FDA seems open to a new end­point that could ac­cel­er­ate the de­vel­op­ment of new treat­ments for mul­ti­ple myelo­ma.

The agency’s On­co­log­ic Drugs Ad­vi­so­ry Com­mit­tee …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER